Hims & Hers falls 6.7% after FTC-linked lawsuits spur investor litigation

What happened

Hims & Hers (HIMS) fell 6.7% on October 14, 2026, after multiple law firms filed class action notices linked to an FTC complaint alleging deceptive practices. The filings covered purchases between August 4, 2025, and July 29, 2026, and noted a November 2, 2026, deadline to seek appointment as lead plaintiff. The session closed at $27.72, and coverage of the litigation coincided with the day’s decline.

How big was the move

The session was unusually large and mostly company-specific: the stock moved far more than the market and its sector. The stock’s move was 1.2 times a typical daily move for this stock, and trading volume was 1.1 times its 20-day average, showing heavier turnover than normal. The S&P 500 fell 1.1% on the day and the Healthcare sector median fell 0.8%, making the stock’s fall 5.9 percentage points worse than the sector median. With a beta of 2.50, the stock tends to move more than the market, which amplified the reaction to the litigation news.

The technical picture

Technically, the shares settled 5.1% below their 20-day moving average and 5.7% below their 50-day moving average, while remaining 1.5% above their 200-day moving average. The stock had been above that indicator for 19 consecutive trading days, and the 50-day average remained above the 200-day average, a sign of an established uptrend. The Relative Strength Index (14 days) stood at 44, putting momentum in a neutral range.

Over three months the stock fell 17.7%, and it was 57.5% below the 52-week high, underscoring that the brief stretch above the 200-day average has not erased a much longer decline. Over one year the stock fell 49.4% and trailed the S&P 500 by 65.3 percentage points. Volatility was elevated: 86% annualized over 60 days, higher than 70% of its own readings over five years.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $2.58 billion, which grew 28.0% from a year earlier. Diluted earnings per share were $-0.63, and earnings per share growth from a year earlier fell 178.3%. Gross margin was 64.7%, down from 76.2% a year earlier, and operating margin was 3.6%, down from 6.2% a year earlier. Free-cash-flow margin was 3.5% and return on invested capital was 3.7%, while free-cash-flow yield was 1.3%.

Those figures present a mixed picture for investors: top-line growth remained healthy at 28.0%, but margins and profitability have contracted sharply year over year. Share count over one year decreased by 9.7%, which may affect per-share metrics and is a detail analysts often account for when revising models. PromtFinance scores are uneven: Value 71 (Positive) and Quality 77 (Positive) contrast with Momentum 30 (Weak), Revisions 1 (Very weak) and Stability 10 (Very weak). That pattern suggests longer-term fundamentals look stronger than near-term sentiment and revision signals.

Investors will note a consensus price target of $32.17, which is 16.1% above the closing price, based on 20 analysts with a consensus rating of Hold. Thirty-five percent of analysts rate the stock Buy, reflecting some support among analysts despite the Hold consensus.

Earnings and analyst expectations

Hims & Hers last reported on August 10, 2026, posting earnings per share of $-0.37 against $-0.05 expected, 643.1% below estimates. The company has recorded consecutive quarters beating estimates of 0, and the average surprise over the last four reports was 100.0% below estimates. The typical two-day reaction after recent reports was that the stock rose 1.3%. The next report is scheduled for November 9, 2026.

The wide gap between reported and expected EPS in August highlights execution risk and the challenge of meeting market expectations. With a consensus rating of Hold and limited analyst upward revision momentum, market participants may be adopting a cautious stance ahead of the next earnings date.

What to watch

• November 2, 2026: deadline to seek appointment as lead plaintiff in the class action filings.
• November 9, 2026: scheduled date for the company’s next earnings report.
• Share count over one year decreased by 9.7%, a change analysts may reference in updates.
• Consensus price target is $32.17, 16.1% above the closing price, with 20 analysts covering and a consensus rating of Hold.